Clinical trial
Improving the Results of Bone Marrow Transplantation for Patients With Severe…
NCT00061568 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00061568 |
|---|---|
| Title | Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias |
| Official title | Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Congenital Hemolytic Anemia, Sickle Cell Disease |
| Intervention type | Drug, Procedure |
| Interventions | Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus |
| Enrollment | 130 |
| Start date | Jul 16, 2004 |
| Primary completion | Jan 20, 2023 |
| Completion | Jan 31, 2026 |
| First posted | May 29, 2003 |
| Last update posted | Feb 29, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: